PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

ANANDRON IN A TREATMENT OF ADVANCED PROSTATIC CARCINOMA CLINIC OF UROLOGY MILITARY MEDICAL ACADEMY ŁÓD¬
Article published in Urologia Polska 1995/48/3.

authors

Marek Pisarski, Eugeniusz Mięko¶
Z Kliniki Urologii ICh WAM
Kierownik Kliniki prof.dr hab. E. Mięko¶

summary

We evaluated the group of six patients with prostatic cancer at age ranging from 61 to 77 years,
including four patients who were followed for longer than one year.
Local disease was controlled by means of digital rectal examination and transrectal ultrasound
with 4 MHz probe. Distant disease was estimated by chest radiogram, scintigram of skeleton, ultra-
sonography of abdominal cavity. Levels of prostate specific antigen (PSA), prostatic fraction of acid
phosphatase and alkaline phosphatase vere also contrrlled.
We used Anandron, in addition to orchiectomy, in a dose of 100 mg 3 times daily for 30 days, and
next in a dose of 50 mg 3 times daily.
In conclusion therapy of Anandron was generally well tolerated, except one patient. None of our
patients had symptoms of toxicity of the drug.

references

  1. 1. Carpentier P., Schroder F.H.: Transrectal ultrasonography in the follow-up of prostatic carci-
  2. noma patiens. J.Urol., 1982, 128,742. ? 2. Catalona W.J., Scott W.W.: Carcinoma of the prostatae:
  3. a review. J.Urol., 1978, 119,1. ? 3. Chodak G.W., Wald V., Palmer E.: Comparison of digital exami-
  4. nation and transrectal ultrasonography for diagnosis of prostatic cancer. J.Urol., 1986,135,951. ?4.
  5. Emtage L.A., Lewis P.W., Blackledge G.P.R.: The role of prostatic specific antigen in the base line
  6. assessment of patiens undergoing hormone therapy for advanced prostatae cancer. Brit.J.Urol., 1987,
  7. 60,572. ? 5. Fourcade R.O., Cariou G., Coloby P.\ Total androgen blockade in the treatment of
  8. advanced prostatae cancer. J.Urol., 1990,145 part 2,221 A. ? 6. Goodman C.M., Busuttil A., Chi-
  9. sholm G.D.: Age, and size and grade of tumor prostatae predict prognosis in incidentaly diagnosed
  10. carcinoma of the prostatae. Brit.J.Urol. 1988, 62,6,576. ? 7. Janknegt R.A., Abbou CC, Bartoletti
  11. R:. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multina-
  12. tional double-blind randomized trial. J.Urol., 1993, 149,77. ? 8. Ojasoo T:. Nilutamid. Drugs of the
  13. future. J.Urol., 1975, 113,834. ? 9. Pontes EJ:. Biochemical markers in prostatae cancer. J.Urol.,
  14. 1983, 130,1037. ? 10. Puser B.N., Robinson B.C., Mostofi F.K.: Comparison of needle biopsy and
  15. transurethral resection biopsy in the diagnosis of carcinoma of the proetatae. J.Urol., 1967, 98,224.
  16. ? 11. Schroder F.H., Cooper E.H., Debruyne F.M.J., Denis L, Newling D. W. W., Pavone-Macalu-
  17. so M., Smith P.H., Syhester R. and Members of the EORT Genitourinary Group: TNM classification
  18. of genitourinary tumors 1987-Position of the EORT Genitourinary Group. Brit.J.Urol., 1988, 62,6,502.
  19. ? 12. Schroder F.H.: Pure antiandrogen as monoteraphy in prospectiv studies of prostatic carcino-
  20. ma. Treatment of prostatic cancer-facts and controversies. EORT Genitourinary Group Monograph
  21. 8: Wiley-Liss 1989,93. ? 13. Stamey T.A., Kobalin J.H., Ferrari M.Jang N.: Prostatae specific
  22. antigen in the diagnosis and treatment of adenocarcinoma of the prostatae. IV Antiandrogen treated
  23. patiens. J.Urol., 1989, 141,1088.? 14. Wajsman Z., Chu T.M., Bross D.: Clinical significance of
  24. serum alkaline phosphatase isoenzyme level with an advanced prostatic cancer. J.Uro 1., 1978,119,244.